Clinical outcomes and predictors for 30-day readmissions of endoscopic retrograde cholangiopancreatography in the United States
- PMID: 37743640
- DOI: 10.1111/jgh.16362
Clinical outcomes and predictors for 30-day readmissions of endoscopic retrograde cholangiopancreatography in the United States
Abstract
Background/objectives: We aimed to assess 30-day readmissions of endoscopic retrograde cholangiopancreatography (ERCP) in the United States.
Methods: The National Readmission Database was utilized from 2016 to 2020 to identify 30-day readmissions of ERCP. Hospitalization characteristics and outcomes were compared between index hospitalizations and readmissions. Predictors of 30-day readmission and mortality were also identified.
Results: Between 2016 and 2020, 885 416 index hospitalizations underwent ERCP. Of these, 88 380 (10.15%) were readmitted within 30 days. Compared to index hospitalizations, 30-day readmissions had higher mean age (63.76 vs 60.8 years, P < 0.001) and proportion of patients with Charlson Comorbidity Index (CCI) score ≥3 (48.26% vs 29.91%, P < 0.001). Sepsis was the most common readmission diagnosis. Increasing age, male gender, higher CCI scores, admissions at large metropolitan teaching hospitals, cholecystectomy on index hospitalization, biliary stenting, increasing length of stay (LOS) at index admission, post-ERCP pancreatitis, post-ERCP hemorrhage, and gastrointestinal tract perforation were independent predictors of 30-day readmissions. Furthermore, 30-day readmissions had higher odds of inpatient mortality (4.42% vs 1.66%, aOR 1.9, 95% CI: 1.79-2.01, P < 0.001) compared to index hospitalizations. However, we noted a shorter LOS (5.78 vs 6.22 days, mean difference 1.2, 95% CI: 1.12-1.28, P < 0.001) and lower total hospital charge ($71 076 vs $93 418, mean difference $31 452, 95% CI: 29 835-33 069, P < 0.001) for 30-day readmissions compared to index hospitalizations. Increasing age, higher CCI scores, increasing LOS, biliary stenting, and post-ERCP hemorrhage were independent predictors of inpatient mortality for 30-day readmissions.
Conclusion: After index ERCP, the 30-day remission rate was 10.15%. Compared to index hospitalizations, 30-day readmissions had higher odds of inpatient mortality.
Keywords: Endoscopic retrograde cholangiopancreatography; Healthcare burden; Mortality; Outcomes; Readmission.
© 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Similar articles
-
The impact of COVID-19 on hospitalizations that underwent endoscopic retrograde cholangiopancreatography in the United States.Surg Endosc. 2024 Jan;38(1):202-211. doi: 10.1007/s00464-023-10529-5. Epub 2023 Nov 13. Surg Endosc. 2024. PMID: 37957298
-
Predictors of 30-Day Readmission After Inpatient Endoscopic Retrograde Cholangiopancreatography: A Single-Center Experience.Dig Dis Sci. 2020 May;65(5):1481-1488. doi: 10.1007/s10620-019-05870-6. Epub 2019 Oct 5. Dig Dis Sci. 2020. PMID: 31587154
-
Evaluation of socioeconomic and healthcare disparities on same admission cholecystectomy after endoscopic retrograde cholangiopancreatography among patients with acute gallstone pancreatitis.Surg Endosc. 2022 Jan;36(1):274-281. doi: 10.1007/s00464-020-08272-2. Epub 2021 Jan 22. Surg Endosc. 2022. PMID: 33481109
-
Clinical Outcomes of Acute Myocardial Infarction Hospitalizations With Systemic Lupus Erythematosus: An Analysis of Nationwide Readmissions Database.Curr Probl Cardiol. 2022 Nov;47(11):101086. doi: 10.1016/j.cpcardiol.2021.101086. Epub 2021 Dec 20. Curr Probl Cardiol. 2022. PMID: 34936910 Review.
-
Sex differences in myocarditis hospitalizations: Rates, outcomes, and hospital characteristics in the National Readmission Database.Curr Probl Cardiol. 2024 Feb;49(2):102233. doi: 10.1016/j.cpcardiol.2023.102233. Epub 2023 Dec 3. Curr Probl Cardiol. 2024. PMID: 38052347 Review.
Cited by
-
Impact of frailty on endoscopic retrograde cholangiopancreatography outcomes in nonagenarians: A United States national experience.World J Gastrointest Endosc. 2024 Mar 16;16(3):148-156. doi: 10.4253/wjge.v16.i3.148. World J Gastrointest Endosc. 2024. PMID: 38577647 Free PMC article.
References
-
- Kröner PT, Bilal M, Samuel R et al. Use of ERCP in the United States over the past decade. Endosc. Int. Open. 2020; 8: E761-E769.
-
- Kozarek RA. The past, present, and future of endoscopic retrograde cholangiopancreatography. Gastroenterol. Hepatol. (N Y). 2017; 13: 620-622.
-
- Carr-Locke DL. Overview of the role of ERCP in the management of diseases of the biliary tract and the pancreas. Gastrointest. Endosc. 2002; 56: S157-S160.
-
- Dahiya DS, Perisetti A, Sharma N et al. Racial disparities in endoscopic retrograde cholangiopancreatography (ERCP) utilization in the United States: are we getting better? Surg. Endosc. 2023; 37: 421-433.
-
- Tarikci Kilic E, Kahraman R, Ozdil K. Evaluation of safety and outcomes of endoscopic retrograde cholangiopancreatography in 1337 patients at a single center. Medeni Med J. 2019; 34: 290-296 Epub 20190927.
MeSH terms
LinkOut - more resources
Full Text Sources